Matches in Wikidata for { <http://www.wikidata.org/entity/Q58041511> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q58041511 description "article" @default.
- Q58041511 description "im November 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58041511 description "wetenschappelijk artikel" @default.
- Q58041511 description "наукова стаття, опублікована в березні 2017" @default.
- Q58041511 name "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 name "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 type Item @default.
- Q58041511 label "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 label "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 prefLabel "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 prefLabel "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplan" @default.
- Q58041511 P1433 Q58041511-EFCEF540-5E73-4FB8-8009-11BD98C61145 @default.
- Q58041511 P1476 Q58041511-06612CA8-3ACC-404B-90E9-A69327FDE6D1 @default.
- Q58041511 P2093 Q58041511-21F996EE-2832-4EEE-9BF5-DE66D3EC7536 @default.
- Q58041511 P2093 Q58041511-44C4223D-F983-475C-B59E-60C78F89AF55 @default.
- Q58041511 P2093 Q58041511-494FFCA0-3AA9-4CF6-811A-4A9A2118DF59 @default.
- Q58041511 P2093 Q58041511-4DDDE880-2C43-406A-8478-9ED486E9B73E @default.
- Q58041511 P2093 Q58041511-60F681E1-4552-467C-A5B9-CA7D09949C37 @default.
- Q58041511 P2093 Q58041511-7BBE39BC-109C-40F3-830B-61D7A3ABB2BE @default.
- Q58041511 P2093 Q58041511-9545A8DE-D509-491F-9E31-F55662AECB4C @default.
- Q58041511 P2093 Q58041511-AE129E61-DA02-4DFA-8F89-E27FDE089B59 @default.
- Q58041511 P2093 Q58041511-BE210E37-792D-4815-AE37-B532F6CDA09F @default.
- Q58041511 P2093 Q58041511-BEC680D9-FAB6-4D0A-A0F1-C937898408FD @default.
- Q58041511 P2093 Q58041511-D55649A8-0E5B-4BA1-AD8D-142B2A13E227 @default.
- Q58041511 P304 Q58041511-7D5724BB-B8B8-4661-8D1D-AF1735510B61 @default.
- Q58041511 P31 Q58041511-BE2D5935-7D29-42FE-918C-EE0E51BC3680 @default.
- Q58041511 P356 Q58041511-879F6FB0-5721-4144-B262-751689B73B06 @default.
- Q58041511 P433 Q58041511-49066908-0987-46D0-B789-29737FD9A213 @default.
- Q58041511 P478 Q58041511-D344FF17-A937-4EBF-8DEA-7737C479ACD5 @default.
- Q58041511 P50 Q58041511-90F2662E-4314-49D7-879C-1D8BC9965C85 @default.
- Q58041511 P50 Q58041511-9F0CBDD9-DC0F-494C-8FD4-2A18AA5D0677 @default.
- Q58041511 P50 Q58041511-AA4C8509-6009-45BB-ACBD-16E330986562 @default.
- Q58041511 P577 Q58041511-DC3B2133-E751-4D8B-A5F3-A0DB45C8D381 @default.
- Q58041511 P698 Q58041511-705309C1-6367-4363-BC73-FD9BE20A6BE9 @default.
- Q58041511 P921 Q58041511-50C9ADA3-A218-4811-8691-03EE67792516 @default.
- Q58041511 P921 Q58041511-62F30CA4-3891-4B59-92F9-7E3999DC2A3D @default.
- Q58041511 P921 Q58041511-D01BAACA-9D70-4FF2-AEAB-D271CE43A998 @default.
- Q58041511 P921 Q58041511-E59EE6F7-BF58-4F24-BF35-A0ED8AE00D26 @default.
- Q58041511 P356 J.BBMT.2016.11.023 @default.
- Q58041511 P698 27914967 @default.
- Q58041511 P1433 Q15754328 @default.
- Q58041511 P1476 "Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation" @default.
- Q58041511 P2093 "Anastasia Athanasiadou" @default.
- Q58041511 P2093 "Apostolia Papalexandri" @default.
- Q58041511 P2093 "Christos Smias" @default.
- Q58041511 P2093 "Chrysanthi Vadikolia" @default.
- Q58041511 P2093 "Chrysavgi Lalayanni" @default.
- Q58041511 P2093 "Damianos Sotiropoulos" @default.
- Q58041511 P2093 "Despina Mallouri" @default.
- Q58041511 P2093 "Evangelia Yannaki" @default.
- Q58041511 P2093 "Ioannis Batsis" @default.
- Q58041511 P2093 "Maria Kaliou" @default.
- Q58041511 P2093 "Varnavas Constantinou" @default.
- Q58041511 P304 "445-451" @default.
- Q58041511 P31 Q13442814 @default.
- Q58041511 P356 "10.1016/J.BBMT.2016.11.023" @default.
- Q58041511 P433 "3" @default.
- Q58041511 P478 "23" @default.
- Q58041511 P50 Q42933010 @default.
- Q58041511 P50 Q54067575 @default.
- Q58041511 P50 Q60227348 @default.
- Q58041511 P577 "2016-11-30T00:00:00Z" @default.
- Q58041511 P698 "27914967" @default.
- Q58041511 P921 Q103824 @default.
- Q58041511 P921 Q264118 @default.
- Q58041511 P921 Q29496 @default.
- Q58041511 P921 Q954625 @default.